This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through March 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
by Zacks Equity Research
CytomX Therapeutics stock surges 44% after phase I data for Varseta-M in heavily pretreated metastatic CRC show rising response rates and strong disease control.
AstraZeneca's Imfinzi Secures Approval for Gastric Cancer in the EU
by Zacks Equity Research
AZN wins the EU nod for Imfinzi in early gastric and GEJ cancers, backed by strong survival data and expanding its blockbuster oncology footprint.
FDA Approves NVS' Cosentyx in Hidradenitis Suppurativa for Adolescents
by Zacks Equity Research
Novartis wins FDA nod to expand Cosentyx use to teens with hidradenitis suppurativa, making it the only IL-17A inhibitor for this group.
United Therapeutics Stock Surges 32% in 6 Months: Here's Why
by Zacks Equity Research
UTHR shares jump 32% in six months as Tyvaso sales surge, earnings grow and Phase III TETON-2 data open a potential new market in IPF.
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It?
by Zacks Equity Research
BEAM shares jump 23% in six months as upbeat risto-cel data, pipeline expansion and new financing strengthen confidence in its gene-editing strategy.
JNJ Seeks Label Expansion of Multiple Myeloma Drug Tecvayli in the EU
by Zacks Equity Research
Johnson & Johnson seeks EMA nod to expand Tecvayli monotherapy use in earlier-line RRMM, backed by phase III MajesTEC-9 data showing strong survival gains.
LLY Wins CHMP Nod for Olumiant's Expanded Use in Alopecia Areata
by Zacks Equity Research
Eli Lilly wins CHMP backing to expand Olumiant use in adolescents with severe alopecia areata, with the EU approval decision expected shortly.
REGN & SNY's Dupixent Gets CHMP Nod for Pediatric Use in Urticaria
by Zacks Equity Research
Regeneron and Sanofi win CHMP backing to expand Dupixent use to young CSU patients, with EU and U.S. decisions poised to unlock a new growth avenue.
RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus
by Zacks Equity Research
Rocket Pharmaceuticals reports narrower-than-estimated Q4 loss. The company provides key updates on its pipeline candidates. Stock rises in after-hours trading.
PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View
by Zacks Equity Research
Puma Biotechnology Q4 earnings top estimates with 28% revenue jump, but weak 2026 outlook sparks 14% after-hours plunge.